Module 2.3 — Quality Overall Summary (QOS) — GLPI-103
| Field | Value |
|---|---|
| Document ID | M23 |
| Version | 2.0 (submission-grade) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist peptide) |
| Sponsor | Virtual Biopharma Inc. |
| Standard | ICH M4Q(R1) §2.3 · Q6A/Q6B · Q1A(R2)/Q5C · Q2(R2) · Q3A/Q3B · Q8–Q11 |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]Summarizes Module 3 (M3, M3-S, M3-P, M3-QTPP, M3-CS, M3-AMV, M3-PV, M3-STAB, M3-AR); illustrative values. No CMC data are generated by this project.
Change History
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC / Quality | Initial version |
| 2.0 | 2026-07-05 | CMC / Quality | Submission-grade — expanded S/P/A/R subsections, control strategy, process/analytical validation, and stability; aligned to the detailed Module 3 leaves |
2.3.Introduction
GLPI-103 is a synthetic peptide dual agonist of the GLP-1 and APJ receptors, presented as two drug products: a sterile solution for once-weekly intravenous use (P-IV) and a once-daily oral immediate-release tablet (P-Oral) containing a permeation enhancer. The quality package is built on a Quality Target Product Profile and Critical Quality Attributes (M3-QTPP) and a control strategy (M3-CS) developed under ICH Q8–Q11 quality-by-design principles.
2.3.S Drug Substance
GLPI-103 drug substance is manufactured by solid-phase peptide synthesis (SPPS) with fatty-acid acylation and non-natural residues, followed by RP-HPLC purification and lyophilization (M3.2.S.2).
- Structure/characterization (S.1/S.3): primary sequence confirmed by peptide mapping and mass spectrometry; higher-order structure and potency established by orthogonal GLP-1R and APJ cell-based assays; process- and product-related impurities (sequence variants/deletions, oxidation, aggregation, residual reagents) characterized (M3-S).
- Control (S.4): specification includes identity, assay (95.0–105.0%), related substances, aggregates by SEC, counter-ion/water content, residual solvents, and bacterial endotoxin, using validated stability-indicating methods (M3-AMV; ICH Q2(R2)).
- Reference standards, container closure, stability (S.5–S.7): qualified primary/working standards; controlled low-temperature storage; ICH Q1A(R2)/Q5C stability supports the retest period (M3-STAB).
2.3.P Drug Product
- P-IV — sterile aqueous solution for once-weekly IV administration; manufactured by aseptic fill–finish with sterility, endotoxin, particulate, and container-closure-integrity control.
- P-Oral — once-daily immediate-release tablet with a permeation enhancer enabling oral peptide absorption; controlled by assay, related substances, dissolution, content uniformity, and disintegration.
Pharmaceutical development (P.2) links formulation and process parameters to the CQAs and to clinical performance (biopharmaceutics, M2.7.1). Both processes are validated across the lifecycle (M3-PV; ICH Q8/Q11); container-closure systems are qualified; ICH stability supports the proposed shelf lives (M3-STAB).
2.3.A Appendices
Facilities and equipment, and adventitious-agents safety, are addressed; adventitious-agent risk is low for a fully synthetic peptide (no biological starting materials). The novel excipient (permeation enhancer) is supported by appropriate qualification (M3-AR §3.2.A).
2.3.R Regional Information
Region-specific quality information (executed batch records, method-validation packages, comparability, and process-validation scheme) is provided per FDA, EMA, and MFDS expectations (M3-AR §3.2.R).
2.3.Conclusion
The Quality (CMC) package supports a well-characterized, consistently manufactured drug substance and two drug products with justified specifications, validated analytical and manufacturing processes, qualified container-closure systems, and adequate stability, consistent with the clinical formulations used across the development program (PROT-301; M2.7.1). The control strategy assures that each batch meets its CQAs, providing a robust quality basis for the marketing application.